Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
57,056,058
-
Total 13F shares
-
6,093,269
-
Share change
-
-1,119,305
-
Total reported value
-
$32,840,000
-
Put/Call ratio
-
11%
-
Price per share
-
$5.39
-
Number of holders
-
30
-
Value change
-
-$7,414,820
-
Number of buys
-
12
-
Number of sells
-
12
Institutional Holders of Astria Therapeutics, Inc. - Common Stock, $0.001 par value per share (ATXS) as of Q4 2021
As of 31 Dec 2021,
Astria Therapeutics, Inc. - Common Stock, $0.001 par value per share (ATXS) was held by
30 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,093,269 shares.
The largest 10 holders included
PERCEPTIVE ADVISORS LLC, RA CAPITAL MANAGEMENT, L.P., Fairmount Funds Management LLC, Cormorant Asset Management, LP, VR Adviser, LLC, VANGUARD GROUP INC, Alyeska Investment Group, L.P., CITADEL ADVISORS LLC, Ikarian Capital, LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
29
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.